List of Dicerna Pharmaceuticals patents

Patents where

Current Assignee

Name

Dicerna Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10131912 Extended dicer substrate agents and methods for the specific inhibition of gene expression	Patent 10131912 was granted and assigned to Dicerna Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10131912	November 20, 2018
‌ US Patent 8349809 Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression	Patent 8349809 was granted and assigned to Dicerna Pharmaceuticals on January, 2013 by the United States Patent and Trademark Office.		Dicerna Pharmaceuticals	United States Patent and Trademark Office	8349809	January 8, 2013
‌ US Patent 8927705 Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression	Patent 8927705 was granted and assigned to Dicerna Pharmaceuticals on January, 2015 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	8927705	January 6, 2015
‌ US Patent 11572559 Reducing beta-catenin expression to potentiate immunotherapy	Patent 11572559 was granted and assigned to Dicerna Pharmaceuticals on February, 2023 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11572559	February 7, 2023
‌ US Patent 11597929 Extended dicer substrate agents and methods for the specific inhibition of gene expression		Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11597929	March 7, 2023
‌ US Patent 11359198 Extended dicer substrate agents and methods for the specific inhibition of gene expression	Patent 11359198 was granted and assigned to Dicerna Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11359198	June 14, 2022
‌ US Patent 11408003 Extended dicer substrate agents and methods for the specific inhibition of gene expression		Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11408003	August 9, 2022
‌ US Patent 11414664 Extended dicer substrate agents and methods for the specific inhibition of gene expression		Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11414664	August 16, 2022
‌ US Patent 11572562 Compositions and methods for inhibiting GYS2 expression		Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11572562	February 7, 2023
‌ US Patent 11351265 Process for formulating an anionic agent	Patent 11351265 was granted and assigned to Dicerna Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11351265	June 7, 2022
‌ US Patent 10144725 Amine cationic lipids and uses thereof	Patent 10144725 was granted and assigned to Dicerna Pharmaceuticals on December, 2018 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10144725	December 4, 2018
‌ US Patent 11504374 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder	Patent 11504374 was granted and assigned to Dicerna Pharmaceuticals on November, 2022 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11504374	November 22, 2022
‌ US Patent 11478501 Compositions and methods for inhibiting HMGB1 expression	Patent 11478501 was granted and assigned to Dicerna Pharmaceuticals on October, 2022 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11478501	October 25, 2022
‌ US Patent 10370655 Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA	Patent 10370655 was granted and assigned to Dicerna Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10370655	August 6, 2019
‌ US Patent 10351854 Therapeutic inhibition of lactate dehydrogenase and agents therefor	Patent 10351854 was granted and assigned to Dicerna Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10351854	July 16, 2019
‌ US Patent 9458457 Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA	Patent 9458457 was granted and assigned to Dicerna Pharmaceuticals on October, 2016 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	9458457	October 4, 2016
‌ US Patent 11359203 Therapeutic inhibition of lactate dehydrogenase and agents therefor	Patent 11359203 was granted and assigned to Dicerna Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11359203	June 14, 2022
‌ US Patent 10150965 Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA	Patent 10150965 was granted and assigned to Dicerna Pharmaceuticals on December, 2018 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10150965	December 11, 2018
‌ US Patent 11060093 Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Patent 11060093 was granted and assigned to Dicerna Pharmaceuticals on July, 2021 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	11060093	July 13, 2021
‌ US Patent 9701966 Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Patent 9701966 was granted and assigned to Dicerna Pharmaceuticals on July, 2017 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	9701966	July 11, 2017
‌ US Patent 8513207 Extended dicer substrate agents and methods for the specific inhibition of gene expression	Patent 8513207 was granted and assigned to Dicerna Pharmaceuticals on August, 2013 by the United States Patent and Trademark Office.		Dicerna Pharmaceuticals	United States Patent and Trademark Office	8513207	August 20, 2013
‌ US Patent 10435692 Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Patent 10435692 was granted and assigned to Dicerna Pharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10435692	October 8, 2019
‌ US Patent 10465195 Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Patent 10465195 was granted and assigned to Dicerna Pharmaceuticals on November, 2019 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10465195	November 5, 2019
‌ US Patent 10487330 Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Patent 10487330 was granted and assigned to Dicerna Pharmaceuticals on November, 2019 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10487330	November 26, 2019
‌ US Patent 10036017 Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA	Patent 10036017 was granted and assigned to Dicerna Pharmaceuticals on July, 2018 by the United States Patent and Trademark Office.	Dicerna Pharmaceuticals	Dicerna Pharmaceuticals	United States Patent and Trademark Office	10036017	July 31, 2018

Results per page:

89 results

0 selected

89 results

0 selected